Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalized anxiety disorder. Its lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnoea. IHL-42X has completed a Phase II clinical trial. PSX-001 is a synthetic psilocybin treatment for the treatment of generalized anxiety disorder. PSX-001 has completed a Phase II clinical trial. IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. IHL-675A is in a Phase II clinical development program.
Código da empresaIXHL
Nome da EmpresaIncannex Healthcare Inc
Data de listagemMar 18, 2022
CEOLatham (Joel)
Número de funcionários12
Tipo de títulosOrdinary Share
Fim do ano fiscalMar 18
Endereço8 Century Circuit
Cidade
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísAustralia
Código postal2153
Telefone61409840786
Site
Código da empresaIXHL
Data de listagemMar 18, 2022
CEOLatham (Joel)
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados